Q-Line Biotech Limited
ListedSMEHealthcare · NSE
Q-Line Biotech Limited is a healthcare diagnostics company engaged in the manufacturing and supply of In-Vitro Diagnostic (IVD) products, pathology reagents, rapid test kits, and laboratory equipment for hospitals, diagnostic laboratories, and healthcare institutions across India. Established in 2010, the company focuses on affordable diagnostic solutions and operates in the medical diagnostics and healthcare consumables segment, with its proposed IPO planned for listing on the NSE EMERGE SME platform.
Price Band
₹326 – ₹343
Issue Size
₹625.32 L Cr
Lot Size
400 shares
GMP
₹95
+27.7%
Est. Listing
₹438
at current GMP
Subscribed
102.49x
overall
Open
21 May 2026
Close
25 May 2026
Allotment
26 May 2026
Refund
27 May 2026
Demat Credit
28 May 2026
Listing
29 May 2026
Last updated 4 months ago
Live Grey Market Premium
Q-Line Biotech Limited GMP Today
Last updated: 29 May 2026
Current Premium
₹95+27.7%
Issue Price (Upper)
₹343
Band: ₹326 – ₹343
Estimated Listing Price
₹438
Upper price + GMP
Lot Size
400 shares
Min investment ₹1,37,200
Estimated Profit / Lot
₹38,000
400 × ₹95
Q-Line Biotech Limited GMP Historical Trend
GMP History
Grey Market Premium trend
+₹95
▲ 0 today
Updated 1 minute ago
Estimated Listing Price
| Date | GMP (₹) | GMP % | Est. Listing |
|---|---|---|---|
| 27 Sep 2026 | +₹95 | 27.7% | ₹438 |
| 26 Sep 2026 | +₹95 | 27.7% | ₹438 |
| 25 Sep 2026 | +₹86 | 24.9% | ₹429 |
GMP is unofficial market data. Not a guarantee of listing performance.
About Q-Line Biotech Limited Public Issue & Market Profile
Q-Line Biotech Limited is bringing an initial public offering (IPO) in the Healthcare sector with an aggregate issue size of ₹62,53,200 Crores. The shares are offered at a price band of ₹326 to ₹343 per equity share on NSE. Currently, traders and retail applicants are calculating expected listing gains and break-even points based on unofficial grey market quotations.
Public Issue & Pricing Context:
Prospective investors can apply in the retail quota with a minimum of 1 lot comprising 400 shares (approx. ₹1,37,200 minimum investment). High net-worth individuals (HNI/NII) can bid in the sHNI (₹2 Lakh to ₹10 Lakh) or bHNI (above ₹10 Lakh) categories for enhanced quota allocation.
Basis of Allotment & Listing Timeline:
Allotment reconciliation will be managed by Purva Sharegistry India Private Limited. Eligible allottees will receive credit of equity shares into their Demat accounts by 2026-05-28, while un-allotted funds or UPI block mandates will be released on 2026-05-27.
Frequently Asked Questions
What is Q-Line Biotech Limited IPO GMP today?
The latest grey market premium for Q-Line Biotech Limited IPO is ₹95, which indicates an expected listing price of ₹438.
What does Kostak Rate and Sauda mean in IPO GMP?
Kostak rate is the profit amount an investor earns by selling their entire IPO application in the grey market before allotment is finalized.
Is Grey Market Premium officially recognized?
No. GMP is an unofficial indicator discovered between dealers outside of SEBI-regulated exchanges. Actual listing price is determined by demand-supply discovery on NSE/BSE during the pre-open auction.